Trial · NCT00307047
Registered outcomes66
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 66
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ischemia Driven Target Lesion Failure (TLF) | 1 year | Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). |
| Secondary | Ischemia Driven Target Vessel Failure (TVF) | 30 days | Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR |
| Secondary | Ischemia Driven Target Vessel Failure (TVF) | 180 days | Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR |
| Secondary | Ischemia Driven Target Vessel Failure (TVF) | 270 days | Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR |
| Secondary | Ischemia Driven Target Vessel Failure (TVF) | 1 year | Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR |
| Secondary | Ischemia Driven Target Vessel Failure (TVF) | 2 years | Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR |
| Secondary | Ischemia Driven Target Vessel Failure (TVF) | 3 years | Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR |
| Secondary | Ischemia Driven Target Lesion Revascularization (TLR) | 30 days | Revascularization of a target lesion associated with any of the following: * positive functional ischemia study * ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Lesion Revascularization (TLR) | 180 days | Revascularization of a target lesion associated with any of the following: * positive functional ischemia study * ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Lesion Revascularization (TLR) | 270 days | Revascularization of a target lesion associated with any of the following: * positive functional ischemia study * ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Lesion Revascularization (TLR) | 1 year | Revascularization of a target lesion associated with any of the following: * positive functional ischemia study * ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Lesion Revascularization (TLR) | 2 years | Revascularization of a target lesion associated with any of the following: * positive functional ischemia study * ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Lesion Revascularization (TLR) | 3 years | Revascularization of a target lesion associated with any of the following: * positive functional ischemia study * ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Vessel Revascularization (TVR) | 30 days | Revascularization of a lesion within the target vessel associated with any of the following: * positive functional ischemia study * ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Vessel Revascularization (TVR) | 180 days | Revascularization of a lesion within the target vessel associated with any of the following: * positive functional ischemia study * ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Vessel Revascularization (TVR) | 270 days | Revascularization of a lesion within the target vessel associated with any of the following: * positive functional ischemia study * ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Vessel Revascularization (TVR) | 1 year | Revascularization of a lesion within the target vessel associated with any of the following: * positive functional ischemia study * ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Vessel Revascularization (TVR) | 2 years | Revascularization of a lesion within the target vessel associated with any of the following: * positive functional ischemia study * ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Target Vessel Revascularization (TVR) | 3 years | Revascularization of a lesion within the target vessel associated with any of the following: * positive functional ischemia study * ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA) * angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study |
| Secondary | Ischemia Driven Major Adverse Cardiac Events (MACE) | 30 days | Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00307047/registered